Sorrell v. IMS Health Inc.
The Court struck down a Vermont law that blocked pharmacies from selling or using doctors' prescription records for pharmaceutical marketing, ruling that the law singled out a particular kind of speech and a particular kind of speaker for disfavored treatment.
Because the law let almost everyone else use the same prescriber data while singling out drug marketers, the Court applied heightened First Amendment scrutiny and found Vermont's privacy and cost-control justifications insufficient to justify the burden on speech.
“The State has burdened a form of protected expression that it found too persuasive. At the same time, the State has left unburdened those speakers whose messages are in accord with its own views. This the State cannot do.”
The core holding that Vermont impermissibly targeted a disfavored message and speaker.
How it got here: A federal trial court upheld Vermont's law; the Second Circuit reversed, finding it unconstitutional; the Supreme Court agreed to hear Vermont's appeal.
The Case in Depth
What happened
Drug companies use "detailing" — sales visits where representatives pitch drugs to doctors — and rely on data about individual doctors' prescribing habits to sharpen their pitches. Pharmacies collect this prescriber information while filling prescriptions and sell it to "data miners," who repackage it for drug manufacturers. Vermont passed a law barring pharmacies from selling this information, or letting it be used, for marketing purposes without a doctor's consent. Data miners and a drug-manufacturer trade group sued, claiming the law violated their free-speech rights.
The question before the Court
Could Vermont bar pharmacies from selling doctors' prescription records to companies that use the data to help drug salespeople pitch brand-name drugs?
The Court's answer
No — the Court ruled that Vermont could not ban pharmacies from selling or using doctors' prescription records for pharmaceutical marketing while letting nearly everyone else use that same data freely. Because the law singled out a specific kind of speech (marketing) and specific speakers (drug companies and their sales reps) for disfavored treatment, the Court applied heightened First Amendment scrutiny rather than treating the law as ordinary economic regulation.
Under that tougher standard, Vermont's justifications — protecting doctor privacy, preventing harassment, and lowering health costs — fell short, because the law left the same information widely available for many other uses and essentially tried to suppress a persuasive but disfavored marketing message. The Court held that fear that speech might be too effective is not a legitimate reason to restrict it.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Pharmaceutical companies and data-mining firms can continue buying and using prescriber records to target sales pitches to doctors, at least without new, more narrowly drawn state restrictions. The ruling also signals that states seeking to control the flow of commercially valuable information by singling out disfavored speakers or messages will face demanding First Amendment scrutiny, affecting future privacy and marketing regulations well beyond pharmaceuticals.
What changes now
The ruling is a final decision on the merits, leaving the Second Circuit's judgment against Vermont's law in place. Vermont's Prescription Confidentiality Law provision at issue can no longer be enforced, though the decision does not prevent states from writing narrower privacy laws that do not single out particular speakers or messages. The case became an important reference point for later disputes over data-privacy and marketing regulations tested against the First Amendment.
What this does not decide
The Court did not decide that all restrictions on data privacy or the sale of personal information violate the First Amendment. It suggested a more evenhanded law restricting sale or disclosure of prescriber data in only a few narrow, well-justified circumstances might survive, leaving room for differently drafted privacy statutes.
Concurrences and dissents
Dissent — Justice Breyer
Justice Breyer argued the law should be reviewed under the lenient standard used for ordinary economic regulation, not heightened First Amendment scrutiny, because the law's only speech effect was withholding data that helped drug companies craft sales pitches. He contended the law easily satisfied even the stricter commercial-speech test because it served substantial interests in privacy, unbiased information, and controlling health costs, with only modest speech-related harm.
How the Court got there
The legal reasoning, step by step
- The Court first asked whether Vermont's law singled out speech based on its content or the identity of the speaker, since laws that do so trigger heightened judicial scrutiny — a tougher constitutional test than ordinary economic regulation receives.
- Reading the statute's text and structure, the Court found that it let prescriber data be bought, sold, and used for almost any purpose except one: marketing by pharmaceutical companies and their detailers. That made the law both content-based (it singled out marketing speech) and speaker-based (it singled out drug manufacturers).
- The Court rejected Vermont's argument that the law merely restricted access to government-generated information rather than protected speech, distinguishing an earlier case (Los Angeles Police Dept. v. United Reporting) because Vermont restricted information already in private hands and the plaintiffs here were asserting their own speech rights, not someone else's.
- The Court also rejected the argument that selling and using the data was mere unprotected conduct, holding that creating and disseminating information is itself speech protected by the First Amendment.
- Having established that heightened scrutiny applied, the Court required Vermont to show the law directly advanced a substantial government interest and was drawn to achieve it. It found the law riddled with exceptions that undercut the stated privacy interest, since doctors' data remained widely available for many other uses.
- The Court concluded that Vermont's true aim was to suppress a persuasive message it disfavored — pharmaceutical marketing — which is not a permissible basis for restricting speech, even under a lenient commercial-speech standard, so the law could not survive heightened scrutiny.
Doctrinal impact
Cases affected by this decision
Distinguishes Los Angeles Police Dept. v. United Reporting Publishing Corp. (528 U. S. 32)
The Court said that case involved restricted access to government-held data, not a burden on the plaintiffs' own speech as here.